vs

Side-by-side financial comparison of MANNATECH INC (MTEX) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $29.2M, roughly 1.2× MANNATECH INC). MANNATECH INC runs the higher net margin — 6.6% vs -304.2%, a 310.8% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -8.1%). MANNATECH INC produced more free cash flow last quarter ($-2.0M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -5.4%).

Mannatech Inc. is a publicly traded, multinational multi-level marketing firm that sells dietary supplements and personal care products. It was founded in November 1993 by Samuel Caster, and is headquartered in Flower Mound, Texas. The company's stock is traded on the NASDAQ exchange under the symbol MTEX. As of 2017, Mannatech employed 252 people and sold its products through some 220,000 independent sales associates.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MTEX vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.2× larger
RXRX
$35.5M
$29.2M
MTEX
Growing faster (revenue YoY)
RXRX
RXRX
+689.8% gap
RXRX
681.7%
-8.1%
MTEX
Higher net margin
MTEX
MTEX
310.8% more per $
MTEX
6.6%
-304.2%
RXRX
More free cash flow
MTEX
MTEX
$45.3M more FCF
MTEX
$-2.0M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-5.4%
MTEX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
MTEX
MTEX
RXRX
RXRX
Revenue
$29.2M
$35.5M
Net Profit
$1.9M
$-108.1M
Gross Margin
76.4%
59.8%
Operating Margin
6.9%
-304.8%
Net Margin
6.6%
-304.2%
Revenue YoY
-8.1%
681.7%
Net Profit YoY
686.6%
39.6%
EPS (diluted)
$1.01
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MTEX
MTEX
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$29.2M
$5.2M
Q2 25
$19.2M
Q1 25
$26.6M
$14.7M
Q4 24
$29.0M
$4.5M
Q3 24
$31.7M
$26.1M
Q2 24
$27.7M
$14.4M
Q1 24
$29.4M
$13.8M
Net Profit
MTEX
MTEX
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$1.9M
$-162.3M
Q2 25
$-171.9M
Q1 25
$-1.5M
$-202.5M
Q4 24
$2.3M
$-178.9M
Q3 24
$-328.0K
$-95.8M
Q2 24
$-624.0K
$-97.5M
Q1 24
$1.2M
$-91.4M
Gross Margin
MTEX
MTEX
RXRX
RXRX
Q4 25
59.8%
Q3 25
76.4%
-183.8%
Q2 25
-4.9%
Q1 25
74.3%
-48.0%
Q4 24
80.6%
-181.4%
Q3 24
74.5%
53.7%
Q2 24
77.1%
36.2%
Q1 24
78.6%
19.1%
Operating Margin
MTEX
MTEX
RXRX
RXRX
Q4 25
-304.8%
Q3 25
6.9%
-3327.6%
Q2 25
-916.8%
Q1 25
-3.1%
-1297.9%
Q4 24
3.0%
-4042.4%
Q3 24
2.8%
-377.1%
Q2 24
-4.1%
-697.4%
Q1 24
2.8%
-698.4%
Net Margin
MTEX
MTEX
RXRX
RXRX
Q4 25
-304.2%
Q3 25
6.6%
-3135.3%
Q2 25
-894.2%
Q1 25
-5.8%
-1373.3%
Q4 24
7.8%
-3935.5%
Q3 24
-1.0%
-367.5%
Q2 24
-2.2%
-676.6%
Q1 24
4.0%
-662.4%
EPS (diluted)
MTEX
MTEX
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$1.01
$-0.36
Q2 25
$-0.41
Q1 25
$-0.80
$-0.50
Q4 24
$1.19
$-0.56
Q3 24
$-0.17
$-0.34
Q2 24
$-0.33
$-0.40
Q1 24
$0.63
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MTEX
MTEX
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$7.1M
$743.3M
Total DebtLower is stronger
$2.9M
$9.6M
Stockholders' EquityBook value
$7.0M
$1.1B
Total Assets
$33.9M
$1.5B
Debt / EquityLower = less leverage
0.42×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MTEX
MTEX
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$7.1M
$659.8M
Q2 25
$525.1M
Q1 25
$9.3M
$500.5M
Q4 24
$11.4M
$594.4M
Q3 24
$12.2M
$427.6M
Q2 24
$9.2M
$474.3M
Q1 24
$7.9M
$296.3M
Total Debt
MTEX
MTEX
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$2.9M
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
MTEX
MTEX
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$7.0M
$1.0B
Q2 25
$919.1M
Q1 25
$7.6M
$933.9M
Q4 24
$8.6M
$1.0B
Q3 24
$10.0M
$524.6M
Q2 24
$8.2M
$584.4M
Q1 24
$10.4M
$401.2M
Total Assets
MTEX
MTEX
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$33.9M
$1.4B
Q2 25
$1.3B
Q1 25
$36.7M
$1.3B
Q4 24
$36.1M
$1.4B
Q3 24
$40.6M
$726.5M
Q2 24
$39.9M
$775.9M
Q1 24
$41.1M
$557.8M
Debt / Equity
MTEX
MTEX
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.42×
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MTEX
MTEX
RXRX
RXRX
Operating Cash FlowLast quarter
$-1.3M
$-46.1M
Free Cash FlowOCF − Capex
$-2.0M
$-47.3M
FCF MarginFCF / Revenue
-6.8%
-133.1%
Capex IntensityCapex / Revenue
2.4%
3.5%
Cash ConversionOCF / Net Profit
-0.68×
TTM Free Cash FlowTrailing 4 quarters
$-1.2M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MTEX
MTEX
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-1.3M
$-117.4M
Q2 25
$-76.4M
Q1 25
$-1.4M
$-132.0M
Q4 24
$-219.0K
$-115.4M
Q3 24
$3.3M
$-59.2M
Q2 24
$-2.7M
$-82.2M
Q1 24
$1.9M
$-102.3M
Free Cash Flow
MTEX
MTEX
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-2.0M
$-117.6M
Q2 25
$-79.6M
Q1 25
$-1.9M
$-133.8M
Q4 24
$-325.0K
$-116.7M
Q3 24
$3.0M
$-63.8M
Q2 24
$-2.7M
$-83.4M
Q1 24
$1.8M
$-109.0M
FCF Margin
MTEX
MTEX
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-6.8%
-2272.5%
Q2 25
-413.9%
Q1 25
-7.0%
-907.4%
Q4 24
-1.1%
-2567.7%
Q3 24
9.5%
-244.6%
Q2 24
-9.9%
-578.5%
Q1 24
6.2%
-789.9%
Capex Intensity
MTEX
MTEX
RXRX
RXRX
Q4 25
3.5%
Q3 25
2.4%
4.7%
Q2 25
16.4%
Q1 25
1.8%
12.4%
Q4 24
0.4%
28.6%
Q3 24
0.8%
17.5%
Q2 24
0.3%
8.2%
Q1 24
0.2%
48.2%
Cash Conversion
MTEX
MTEX
RXRX
RXRX
Q4 25
Q3 25
-0.68×
Q2 25
Q1 25
Q4 24
-0.10×
Q3 24
Q2 24
Q1 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons